1. Signaling Pathways
  2. Apoptosis
    Metabolic Enzyme/Protease
  3. Glutathione Peroxidase

Glutathione Peroxidase

Glutathione peroxidases (GPx) are a family of enzymes with the ability to reduce organic and inorganic hydroperoxides to the corresponding alcohols using glutathione or thioredoxin as an electron donor. These enzymes promote hydrogen peroxide metabolism and protect cell membrane structure and function from oxidative damage. Dysregulated GPx expression is connected with severe pathologies, including obesity and diabetes. GPx1 has been reported to be involved in both pro- and anticancer effects in different tumor models.

In mammals, the GPxs family consists of eight members (GPx1-GPx8) identified so far; five of them (GPx1-GPx4 and GPx6) contain selenocysteine in the catalytic center and the other three are cysteine-containing proteins. GPx1 is one of the most critical members of the GPxs family that catalytically reduces hydrogen peroxide to produce water. The function of GPx3 is to scavenge H2O2 and lipoperoxides in the plasma to reduce systematic oxidative stress and to maintain the bioavailability of vascular nitric oxide. Gpx4 is an essential mammalian glutathione peroxidase, which protects cells against detrimental lipid peroxidation and governs a novel form of regulated necrotic cell death, called ferroptosis.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-100218A
    RSL3
    Inhibitor 99.90%
    RSL3 ((1S,3R)-RSL3) is an inhibitor of glutathione peroxidase 4 (GPX4) (ferroptosis activator), reduces the expression of GPX4 protein, and induces ferroptotic death of head and neck cancer cell. RSL3 increases the expression of p62 and Nrf2 and inactivates Keap1 in HN3-rslR cells.
    RSL3
  • HY-100003
    ML-210
    Inhibitor 99.87%
    ML-210 is a selective and covalent glutathione peroxidase 4 (GPX4) inhibitor with an EC50 of 30 nM. ML-210 binds the GPX4 selenocysteine residue. ML-210 has anti-cancer activity.
    ML-210
  • HY-100002
    ML162
    Inhibitor 99.45%
    ML162 is a covalent glutathione peroxidase 4 (GPX4) inhibitor. ML162 has a selective lethal effect on mutant RAS oncogene-expressing cell lines
    ML162
  • HY-138153
    JKE-1674
    Inhibitor 99.54%
    JKE-1674 is an orally active glutathione peroxidase 4 (GPX4) inhibitor and an active metabolite of GPX4 inhibitor ML-210. JKE-1674, an analog of ML-210 in which the nitroisoxazole ring is replaced with an α-nitroketoxime. JKE-1674 can convert into a nitrile oxide JKE-1777. JKE-1674 kills LOX-IMVI cells in a manner that is equipotent to ML-210 and is completely rescued by ferroptosis inhibitors.
    JKE-1674
  • HY-Y0669
    Pipecolic acid
    Inhibitor ≥98.0%
    Pipecolic acid is a metabolite of lysine and an important precursor for many useful microbial secondary metabolites. Pipecolic acid slows ferroptosis in diabetic retinopathy by inhibiting the YAP-GPX4 signaling pathway. In addition, Pipecolic acid can be used as a diagnostic marker for pyridoxine-dependent epilepsy.
    Pipecolic acid
  • HY-161929
    GPX4 activator 2
    Activator
    GPX4 activator 2 (Compound C3) is an activator of GPX4. GPX4 activator 2 exhibits cardioprotective effects and can inhibit cellular ferroptosis (EC50 = 7.8 μM)。GPX4 activator 2 can be used in the research of myocardial injury.
    GPX4 activator 2
  • HY-Y0669R
    Pipecolic acid (Standard)
    Inhibitor
    Pipecolic acid (Standard) is the analytical standard of Pipecolic acid. This product is intended for research and analytical applications. Pipecolic acid is a metabolite of lysine and an important precursor for many useful microbial secondary metabolites. Pipecolic acid slows ferroptosis in diabetic retinopathy by inhibiting the YAP-GPX4 signaling pathway. In addition, Pipecolic acid can be used as a diagnostic marker for pyridoxine-dependent epilepsy.
    Pipecolic acid (Standard)
  • HY-168011
    GPX4-IN-14
    Inhibitor
    GPX4-IN-14 (compound 2c) is an inhibitor of GPX4, with free radical scavenging activity (maximum scavenging rate is 72.52%) and anti-tumor proliferation activity in vitro. GPX4-IN-14 inhibits GPX4 protein, increases lipid peroxide levels and intracellular Reactive Oxygen Species (ROS) levels, thereby inducing ferroptosis and exerting anti-tumor proliferation effects.
    GPX4-IN-14
  • HY-B0182
    Carmofur
    Inhibitor 99.95%
    Carmofur (HCFU) is a rat recombinant acid ceramidase inhibitor with an IC50 of 29 nM. Carmofur is also a protease inhibitor of SARS-CoV-2 main protease (Mpro), fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amidase (NAAA). Carmofur has anti-cancer, anti-inflammatory and anti-virus activities, and can be used for the study of COVID-19 and acute lung injury (ALI).
    Carmofur
  • HY-141809
    GPX4-IN-3
    Inhibitor 99.90%
    GPX4-IN-3 (26a) is a potent glutathione peroxidase 4 (GPX4) inhibitor as a selective ferroptosis inducer. GPX4-IN-3 (26a) exhibits 71.7% inhibition for GPX4 with 1 μM.
    GPX4-IN-3
  • HY-N0070
    Solasonine
    Inhibitor 99.19%
    Solasonine is a ferroptosis inducer which can be isolated from Solanum melongena that has anti-infection, anti-cancer, and neurogenesis promoting properties. Solasonine promotes ferroptosis of HCC cells via destruction of the glutathione redox system induced by inhibiting GPX4, and can be used for cancer research.
    Solasonine
  • HY-17646
    Verdiperstat
    Inhibitor 99.85%
    Verdiperstat (AZD3241) is a selective, irreversible and orally active myeloperoxidase (MPO) inhibitor, with an IC50 of 630 nM, and can be used in the research of neurodegenerative brain disorders.
    Verdiperstat
  • HY-115627
    PKUMDL-LC-101-D04
    Activator 99.43%
    PKUMDL-LC-101-D04 (GPX4-Activator-1d4) is a glutathione peroxidase 4 (GPX4) allosteric activator (pEC50=4.7). PKUMDL-LC-101-D04 can inhibit ferroptosis and inflammation.
    PKUMDL-LC-101-D04
  • HY-111341
    AZD5904
    Inhibitor 99.93%
    AZD5904 is a selective and irreversible inhibitor of human Myeloperoxidase (MPO) with an IC50 of 140 nM and has similar potency in mouse and rat.
    AZD5904
  • HY-145581
    Mitiperstat
    99.12%
    Mitiperstat (AZD4831) is an effective oral inhibitor of myeloperoxidase (MPO). Mitiperstat can reduce inflammation and improve microvascular function, and it can be used in studies related to heart failure, preserved or mildly reduced ejection fraction, non-alcoholic fatty liver disease, and chronic obstructive pulmonary disease.
    Mitiperstat
  • HY-120912
    Gingerenone A
    Activator 99.70%
    Gingerenone A is an Nrf2-Gpx4 activator that can induce Ferroptosis in liver damage with oral activity. Gingerenone A has anti-inflammatory, anti-diabetic, anti-tumor, and pro-aging effects in mice.
    Gingerenone A
  • HY-100873
    PF-1355
    Inhibitor 99.80%
    PF-1355 is a selective 2-thiouracil mechanism-based MPO inhibitor, used for treatment of vasculitic diseases.
    PF-1355
  • HY-106228
    HLF1-11
    Inhibitor 99.91%
    HLF1-11, a human lactoferrin-derived peptide, is a broad spectrum antimicrobial agent. HLF1-11 inhibits human MPO activity. HLF1-11 also directs GM-CSF-driven monocyte differentiation toward macrophages, and enhances immune responses.
    HLF1-11
  • HY-N4288
    4-Methylesculetin
    Inhibitor 98.21%
    4-Methylesculetin is an orally active coumarin derivative, with potent anti-oxidant and anti-inflammatory activities. 4-Methylesculetin inhibits myeloperoxidase activity. 4-Methylesculetin protects bone resorption by reducing the elevated levels of bone-joint exoglycosidases, cathepsin-D and tartrate resistant acid phosphatases. 4-Methylesculetin ameliorats the upregulated non-enzymatic inflammatory markers like TNF-α, IL-1β, IL-6, COX-2 and PGE2, which is promising for research of inflammatory diseases.
    4-Methylesculetin
  • HY-115486
    MPO-IN-28
    Inhibitor 99.28%
    MPO-IN-28 (Compound 28) is a myeloperoxidase (MPO) inhibitor with an IC50 of 44 nM.
    MPO-IN-28
Cat. No. Product Name / Synonyms Application Reactivity